MA52691A - STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES - Google Patents

STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES

Info

Publication number
MA52691A
MA52691A MA052691A MA52691A MA52691A MA 52691 A MA52691 A MA 52691A MA 052691 A MA052691 A MA 052691A MA 52691 A MA52691 A MA 52691A MA 52691 A MA52691 A MA 52691A
Authority
MA
Morocco
Prior art keywords
synucleinopathies
treatment
methods
statin compositions
statin
Prior art date
Application number
MA052691A
Other languages
French (fr)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MA52691A publication Critical patent/MA52691A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37Coumarins, e.g. psoralen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA052691A 2017-07-03 2018-07-03 STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES MA52691A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762528204P 2017-07-03 2017-07-03

Publications (1)

Publication Number Publication Date
MA52691A true MA52691A (en) 2021-03-31

Family

ID=64950317

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052691A MA52691A (en) 2017-07-03 2018-07-03 STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES

Country Status (14)

Country Link
US (1) US20200113899A1 (en)
EP (1) EP3648756A4 (en)
JP (1) JP2020526487A (en)
KR (1) KR20200026925A (en)
CN (1) CN111093647A (en)
AU (1) AU2018298012A1 (en)
BR (1) BR112020000021A2 (en)
CA (1) CA3105337A1 (en)
EA (1) EA202090194A1 (en)
IL (1) IL271758A (en)
MA (1) MA52691A (en)
MX (1) MX2019015280A (en)
TW (1) TW201906605A (en)
WO (1) WO2019010146A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12502370B2 (en) * 2019-04-11 2025-12-23 Cmpd Licensing, Llc Wound treatments and compositions
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US12156875B2 (en) 2019-04-11 2024-12-03 Cmpd Licensing, Llc Wound treatments and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109990A2 (en) * 2008-01-24 2009-09-11 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of pramipexole
WO2010010136A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and an anti-inflammatory agent for the treatment of parkinson's disease
JP2016528276A (en) * 2013-08-21 2016-09-15 レスバーロジックス コーポレイション Composition and therapy for promoting plaque regression

Also Published As

Publication number Publication date
EA202090194A1 (en) 2020-05-27
MX2019015280A (en) 2020-08-17
EP3648756A1 (en) 2020-05-13
TW201906605A (en) 2019-02-16
WO2019010146A1 (en) 2019-01-10
BR112020000021A2 (en) 2020-07-21
US20200113899A1 (en) 2020-04-16
IL271758A (en) 2020-02-27
CA3105337A1 (en) 2019-01-10
EP3648756A4 (en) 2021-03-31
CN111093647A (en) 2020-05-01
AU2018298012A1 (en) 2020-02-13
KR20200026925A (en) 2020-03-11
JP2020526487A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
EP3377042A4 (en) SUBSTANCES AND METHODS FOR THE TREATMENT OF MYOPATHIES BASED ON TITINE AND OTHER TITINOPATHIES
EP3645739A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MA45290A (en) PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS
EP3704239A4 (en) CASZ COMPOSITIONS AND METHODS OF USE
MA45270A (en) COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
EP3630072A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF EXCESSIVE DROWSINESS
FR24C1010I2 (en) DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH
EP3634430A4 (en) MULTIBIOTIC AGENTS AND METHODS OF USE THEREOF
MA52691A (en) STATIN COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES
EP3474879A4 (en) COMPOSITIONS AND METHODS FOR TREATING MELANOMA
MA47688A (en) USEFUL COMPOSITIONS IN THE TREATMENT OF SPINAL AMYOTROPHY
EP3612215A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY INFLAMMATION
MA71705A (en) SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
MA45688A (en) COMPOSITIONS AND METHODS FOR THE POTENTIALIZATION OF ANTIMICROBIAL AGENTS
MA50849A (en) SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
EP3341391A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
MA46427A (en) COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
EP3735325A4 (en) SURFACE TREATMENT COMPOSITIONS AND METHODS
EP3390642A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PIGMENT RETINITY 18 AND PIGMENT RETINITY 13
MA53873A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA
EP3833340A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYTIA
MA55821A (en) 5-HT2A ANTAGONISTS FOR USE IN THE TREATMENT OF DEPRESSION
EP3448421A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SURGICAL ADHESIONS
MA49248A (en) FGFR2 INHIBITORS USED IN THE TREATMENT OF CHOLANGIOCARCINOMA
EP3645120A4 (en) NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF DEPRESSION